August 26, 2025Hepatology CommunicationsOpen Access

Leukemia inhibitory factor promotes human cholangiopathies, and its inhibition improves cholestasis in Abcb4 −/− mice

View Full Paper

Ask AI

Bookmark

Inhibition of LIF improved cholestasis and reduced liver injury in Abcb4 −/− mice, showing therapeutic promise for cholangiopathies.
LRI-310 administration led to significant reductions in markers of fibrosis and inflammation, highlighting the drug's potential efficacy.
Single-cell transcriptomics revealed high LIF expression in cholangiocytes, correlating with fibrosis and immune activation in PSC and PBC patients.
LIFR antagonism may enable novel therapeutic strategies for immune-mediated cholestatic disorders, warranting further investigation.

Discussion

No takes yet. Share an insight, caveat, or question.

LIFR antagonism reduces cholestasis and fibrosis in a mouse model of PSC, highlighting its therapeutic potential in cholangiopathies.

Giorgio et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark